Sharing insights from a recent webAIRS case study, Dr Clayton Lam joins the podcast for a kōrero on the impacts an increased use of glucagon-like peptide-1 (GLP-1) and off-label GLP-1 agonists is having on perioperative anaesthesia care, as reported to webAIRS. The case series of incidents reported to webAIRS relating to GLP-1 agonist use written by Dr Clayton Lam, Dr D-Yin Lin, and ANZTADC Director Dr Yasmin Endlich has recently been accepted for publication in Anaesthesia and Intensive Care. Want to know more about webAIRS (Anaesthetic Incident Reporting System) visit their website: www.anztadc.net Show notes: ANZCA – Clinical practice recommendation on periprocedural use of GLP-1/GIP receptor agonist:  https://www.anzca.edu.au/resources/professional-documents/endorsed-guidelines/periprocedural-glp-1-use-consensus-clinical-guide.pdf American Association of Anesthesiologists - Most patients can continue diabetes, weight loss GLP-1 drugs before surgery, those at highest risk for GI problems should follow liquid diet before procedure: https://www.asahq.org/about-asa/newsroom/news-releases/2024/10/new-multi-society-glp-1-guidance Australian Society of Anaesthetists – Perioperative management of patients on GLP-1 receptor agonists (GLP-1 Ras): https://asa.org.au/wp-content/uploads/2024/10/ASA-FS1-Perioperative-Management-of-Patients-on-GLP-1-Receptor-Agonists-GLP-1-RAs.pdf